Vir Biotechnology, Inc.
VIR
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.9B
$11.50
▼ -1.12%
P/E
-6.22
Mkt Cap
$1.9B
52-Wk Range
$4.75–$11.94
52-Week Range
$4.75 - $11.94
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 108.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary viral immunology platform enabling rapid therapeutic development
- Strategic partnerships with pharmaceutical giants (GSK, Alnylam, Gilead) providing distribution and credibility
- First-mover advantage with FDA-approved Xevudy generating commercial revenue
- Access to world-class manufacturing through Samsung Biologics partnership
- Funding validation from Bill & Melinda Gates Foundation and NIH demonstrating scientific merit
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Revenue decline expected
Expanding Xevudy market penetration globally for COVID-19 treatment and prevention
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+31.1% over 3m
Quality
Excellent
High-growth business (214% revenue growth, 170% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying VIR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 5, 2026
Reported EPS of $0.47 vs $0.33 consensus (+41.3% surprise). Revenue of $238.9M vs $135.9M expected (+75.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+41.3%
Revenue trend · last 8Q
—
-26%
-95%
-61%
-90%
+418%
-101%
+19583%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.4M
$12.4M
$3.0M
$1.2M
$240.0K
$64.1M
-$29.0K
$238.9M
Margins · last 8Q
Gross
0.0%
Operating
30.8%
Profit
33.5%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 10, 2026
vs Industry
How VIR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related